DAVID POPLACK to Drug Administration Schedule
This is a "connection" page, showing publications DAVID POPLACK has written about Drug Administration Schedule.
Connection Strength
0.284
-
Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol. 1993 Sep; 11(9):1795-803.
Score: 0.024
-
Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res. 1992 Jun 15; 52(12):3503-5.
Score: 0.022
-
Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res. 1992 Feb 01; 52(3):521-4.
Score: 0.022
-
A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. Cancer Chemother Pharmacol. 1992; 30(2):155-7.
Score: 0.022
-
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs. 1990 May; 8(2):181-2.
Score: 0.019
-
The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med. 1989 Feb 15; 110(4):279-85.
Score: 0.018
-
Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Am J Pediatr Hematol Oncol. 1989; 11(3):324-6.
Score: 0.018
-
The pharmacology of orally administered chemotherapy. A reappraisal. Cancer. 1986 Jul 15; 58(2 Suppl):473-80.
Score: 0.015
-
Very high dose cyclophosphamide with imidazole carboximide and vincristine sulfate in the treatment of stage IV neuroblastoma. Am J Clin Oncol. 1985 Jun; 8(3):210-4.
Score: 0.014
-
Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol. 1985 Apr; 3(4):485-9.
Score: 0.013
-
Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res. 1984 Nov; 44(11):4929-32.
Score: 0.013
-
Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. 1981 Sep; 41(9 Pt 1):3343-6.
Score: 0.011
-
Treatment of acute lymphoblastic leukemia in relapse: efficacy of a four-drug reinduction regimen. Cancer Treat Rep. 1981; 65 Suppl 4:93-6.
Score: 0.010
-
Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):26-30.
Score: 0.009
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.008
-
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
Score: 0.008
-
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43.
Score: 0.008
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.007
-
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):774-82.
Score: 0.007
-
Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995 May; 13(5):1238-41.
Score: 0.007
-
Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res. 1990 Nov 15; 50(22):7226-31.
Score: 0.005
-
Phase II study of 5-azacytidine in sarcomas of bone. Am J Clin Oncol. 1982 Aug; 5(4):411-5.
Score: 0.003
-
Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer. 1978 Mar; 41(3):1059-63.
Score: 0.002